Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Expands By 6.3%

Krystal Biotech, Inc. (NASDAQ:KRYSGet Rating) was the target of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 1,190,000 shares, a growth of 6.3% from the February 13th total of 1,120,000 shares. Based on an average daily trading volume, of 189,800 shares, the days-to-cover ratio is currently 6.3 days. Currently, 5.7% of the shares of the stock are short sold.

Insider Transactions at Krystal Biotech

In other news, Director Dino A. Rossi sold 40,000 shares of Krystal Biotech stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the completion of the transaction, the director now owns 83,691 shares of the company’s stock, valued at approximately $6,967,275.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Dino A. Rossi sold 40,000 shares of Krystal Biotech stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the completion of the sale, the director now owns 83,691 shares in the company, valued at approximately $6,967,275.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Krish S. Krishnan sold 3,748 shares of Krystal Biotech stock in a transaction dated Wednesday, January 4th. The stock was sold at an average price of $80.08, for a total value of $300,139.84. Following the sale, the chief executive officer now owns 1,763,688 shares of the company’s stock, valued at approximately $141,236,135.04. The disclosure for this sale can be found here. Insiders sold 89,745 shares of company stock valued at $7,344,570 in the last 90 days. 17.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently modified their holdings of KRYS. MetLife Investment Management LLC lifted its position in Krystal Biotech by 8.9% during the 3rd quarter. MetLife Investment Management LLC now owns 11,181 shares of the company’s stock worth $779,000 after acquiring an additional 915 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Krystal Biotech by 25.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,477 shares of the company’s stock worth $242,000 after acquiring an additional 710 shares in the last quarter. Monarch Partners Asset Management LLC lifted its position in Krystal Biotech by 214.7% during the 3rd quarter. Monarch Partners Asset Management LLC now owns 46,494 shares of the company’s stock worth $3,241,000 after acquiring an additional 31,719 shares in the last quarter. Privium Fund Management B.V. lifted its position in Krystal Biotech by 62.1% during the 3rd quarter. Privium Fund Management B.V. now owns 7,262 shares of the company’s stock worth $512,000 after acquiring an additional 2,782 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in Krystal Biotech by 23.2% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 40,656 shares of the company’s stock worth $2,834,000 after acquiring an additional 7,663 shares in the last quarter. 80.80% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $74.35 on Friday. The firm has a market capitalization of $1.92 billion, a P/E ratio of -13.49 and a beta of 0.87. Krystal Biotech has a 1-year low of $47.67 and a 1-year high of $89.59. The business’s 50-day simple moving average is $78.71 and its 200-day simple moving average is $75.29.

Krystal Biotech (NASDAQ:KRYSGet Rating) last released its quarterly earnings data on Monday, February 27th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.01. On average, equities research analysts expect that Krystal Biotech will post -5.57 EPS for the current fiscal year.

Analyst Ratings Changes

KRYS has been the subject of several recent analyst reports. Chardan Capital restated a “buy” rating and issued a $133.00 price target on shares of Krystal Biotech in a report on Tuesday, February 28th. The Goldman Sachs Group upgraded Krystal Biotech from a “neutral” rating to a “buy” rating and lifted their price target for the company from $79.00 to $124.00 in a report on Tuesday, February 28th. Guggenheim restated a “buy” rating and issued a $101.00 price target on shares of Krystal Biotech in a report on Tuesday, February 28th. Finally, HC Wainwright restated a “buy” rating and issued a $119.00 price target on shares of Krystal Biotech in a report on Tuesday, February 28th.

About Krystal Biotech

(Get Rating)

Krystal Biotech, Inc is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases.

Featured Articles

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.